BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY PARTNERSHIP WITH DNX
This article was originally published in The Gray Sheet
Executive Summary
BAXTER INVESTS $20 MIL. IN TRANSPLANT TECHNOLOGY PARTNERSHIP WITH DNX, according to the companies. The new entity, Nextran, will seek to develop and commercialize technologies "to improve the success and increase the availability of organ transplantation." Under the terms of the agreement, Baxter will own 70% of Nextran, and Princeton, New Jersey-based DNX will hold 30% of the firm. Nextran will operate as an affiliate of Baxter.